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cagPAI cag Pathogenicity Island 
CD-CV Common disease-common variant 
CDH13 cadherin 13 
CM CagA Multimerization 
CNV  Copy number variation 
CO2 Carbon dioxide 
13C Carbon-13 
14C Carbon-14 
Csk Carboxy-Terminal Src Kinase 
DDBJ DNA Database of Japan 
DNA Deoxyribose nucleic acid 
dNTPs Deoxynucleotid Triphosphate 
DRAM1 DNA-damage regulated autophagy modulator 1 
DSB Double strand breaks 
dsDNA  Double strand DNA 
DU Duodenal Ulcer 
dupA Duodenal Ulcer Promoting Gene A 
E-CM East Asian- CagA Multimerization 
EDTA Ethylene Diamine Tetra Acetic Acid 
EMBL European Molecular Biology Laboratory 
EPIYA motif Glu-Pro-Ile-Tyr-Ala Motif 
EtOH Ethanol  
GERD Gastro-esophageal reflux disease 
GC Gastric Cancer 
GTC Genotype console software 
GU Gastric Ulcer 
HWE Hardy Weinberg Equilibrium 
GWAS Genome wide association study 
H. pylori Helicobacter pylori 
HopZ H. pylori Outer Membrane Protein Z 
IARC International Agency for Research in Cancer 
iceA Induced by Contact to Epithelium 
MAF Minor allele frequency 
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MALToma Mucosa Associated Lymphoid Tissue Lymphoma 
MAST4 microtubule associated serine/threonine kinase family member 4 
min  Minute  
mg miligram 
ml  Mililitre  
μl Microliter  
μg Microgram 
μM Micromole  
MLST Multi Locus Sequence Typing 
MMEJ Microhomology-mediated end joining 
MMR Mismatch Repair System 
MPCR Multiplex PCR 
n Number 
RUT Rapid Urease Test 
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KEVIRULENAN KHUSUS HELICOBACTER PYLORI DAN FAKTOR 
KERENTANAN GENETIK PERUMAH: POTENSI PERANAN TERHADAP 
PENYAKIT GASTRODUODENAL 
ABSTRAK 
Helicobacter pylori (H. pylori) adalah salah satu patogen manusia yang paling lazim 
dan memberi kesan terhadap 50% daripada populasi manusia.  H. pylori dikaitkan 
dengan penyakit gastrik, ulser peptik, kanser gastrik dan limfoma berkaitan dengan 
tisu limfoid mukosa gastrik.  Tindak balas beberapa faktor seperti persekitaran, 
kevirulenan bakteria dan genetik hos dipercayai boleh menentukan tahap 
kemudaratan dan kesan selepas jangkitan H. pylori.  Tujuan kajian ini adalah untuk 
menentukan distribusi gen-gen virulen H. pylori (cagA, babA2, SabA dan dupA) dan 
korelasinya dengan hasil klinikal.  Kajian ini juga bertujuan menilai corak H. pylori 
cagA motif EPIYA;  EPIYA-A, -B, -C atau -D di antara kumpulan etnik dan 
perkaitannya dengan penyakit gastroduodenal. Kajian ini turut mengenalpasti 
kehadiran SNP sebagai varian genetik di dalam genom perumah yang mungkin 
berkait dengan kerentanan atau pertahanan tarhadap jangkitan H. pylori. Ini adalah 
kajian keratan rentas dan kajian kes kawalan di antara Mei 2012 sehingga Jun 2014 
dalam kalangan pesakit dispeptik dan berlainan kaum (Melayu, India dan Cina) di 
Unit Endoskopi Hospital Universiti Sains Malaysia dan Hospital Kuala Lumpur.  
Genotyping genom perumah dilakukan  dengan mengunakan teknik PCR dan 
Affymetrix SNP microarray 6.0. Kajian ini merangkumi dua fasa; dalam fasa 
pertama, sejumlah 105 pesakit yang disahkan positif terhadap jangkitan H. pylori 
telah terlibat dalam kajian ini. Purata umur dan SD adalah 54.48+12.94 tahun dengan 
julat umur di antara 26 sehingga 86 tahun.  Lima puluh tujuh (54.3%) pesakit yang 
dijangkiti adalah lelaki manakala empat puluh lapan (45.7%) adalah wanita.  
Berdasarkan penemuan endoskopik, 78 pesakit mengalami gastritis, sembilan gastrik 
ulser, lima ulser duodenal dan 13 normal.  Penemuan gen-gen H. pylori cagA, 
babA2, sabA2 dan dupA dalam pesakit dispeptik H. pylori masing-masing adalah 
69.5%, 41.0%, 43.8% dan 22.9%. Gen cagA dikesan dengan lebih tinggi dalam 
kalangan bangsa India (39.7%), babA2 lebih lazim bagi Melayu (39.5%) manakala 
dupA adalah tertinggi bagi kalangan bangsa India dan Melayu dengan kadar yang 
sama (37.5%).  Bangsa Cina mempunyai kelaziman paling rendah terhadap keempat-
 xxiv 
empat gen.  Majoriti pesakit Cina dijangkiti dengan cagA jenis A-B-D strain Asia 
Timur (88.9%) manakala cagA jenis A-B-C strain Barat (82.8%) dikesan lebih tinggi 
dalam kalangan bangsa India. Bangsa Melayu mempunyai strain bercampur.  
Terdapat perkaitan yang signifikan secara statistik (p<0.001) di antara etnik dan 
cagA motif EPIYA, walaupun tiada perbezaan signifikan di antara gen virulen H. 
pylori dan jenis EPIYA dengan hasil klinikal.  Dalam fasa kedua, sejumlah 80 (42 H. 
pylori positif) dan 38 (H. pylori negatif) pesakit generasi ketiga dengan purata umur 
49.87+12.335 (umur di antara 20-75 tahun).  Kajian ini menunjukkan bahawa SNP 
rs3770521 (P=1.33 X10
-5
) gen XRCC5, rs7042986 (P=0.0001) gen SMARCA2, dan 
rs10860808 (P=0.0002) gen DRAM1 adalah SNP yang cenderung kepada jangkitan 
H. pylori dalam kalangan pesakit gastrik berbangsa India, Melayu dan Cina.  Kajian 
ini turut mengenalpasti dua SNP yang protektif, iaitu rs1809758 (P=9.85X 10
-6
) gen 
BANK1 dan rs3776349 (P=0.0001) gen ARHGAP26 dalam kalangan pesakit gastrik 
India dan Melayu. Kesimpulannya, gen yang rendah dan variasi dalam kumpulan 
etnik yang berlainan menunjukkan strain bakteria tersebut bergantung kepada 
perbezaan etnik dan geografi.  Kajian ini juga menunjukkan bahawa tiada perbezaan 
yang signifikan di antara gen virulen dengan hasil klinikal.  Kajian ini turut 
membuktikan bahawa EPIYA A-B-D dan A-B-C adalah predominan dalam bangsa 
Cina dan India manakala bangsa Melayu mempunyai strain campuran.  Akhir sekali, 
kajian GWAS terkini menunjukkan lima SNP unggul yang boleh dikaitkan dengan 
kecenderungan dan ketahanan terhadap H. pylori gastritis dalam ketiga-tiga 
kumpulan etnik ini. 
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SPECIFIC HELICOBACTER PYLORI VIRULENCE AND HOST GENETIC 
SUSCEPTIBILITY FACTORS: THE POTENTIAL ROLE IN 
GASTRODUODENAL DISEASES 
 
ABSTRACT 
 
Helicobacter pylori (H. pylori) is one of the most common human pathogens and 
affects over 50% of the world population.  H. pylori is associated with gastritis, 
peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid tissue 
lymphoma. The interaction of several factors like environmental, bacterial virulence 
and host genetic are believed to determine the severity and final outcome after H. 
pylori infection. The aim of this study was to determine the distribution of H. pylori 
virulence genes (cagA, babA2, SabAand dupA) and its correlation with clinical 
outcomes. This study also assessed the pattern of H. pylori cagA EPIYA motifs, 
EPIYA-A, -B, -C, or -D among different ethnic groups and its association with 
gastroduodenal disease. The current study also explored the presence of SNPs as 
genetic variants in the host genome which may be associated with susceptibility or 
protection to H. pylori infection. This was a cross-sectional and case-control study 
conducted between May 2012 to June 2014 among dyspeptic patients of different 
ethnicities (Malay, Indian and Chinese) at the Endoscopy Unit of Hospital Universiti 
Sains Malaysia and Hospital Kuala Lumpur. Genotyping of bacterial and host 
genome was performed using PCR and Affymetrix SNP 6.0 microarray. This study 
consists of 2 phases; in phase 1, a total of 105 patients who were confirmed positive 
to have H. pylori infection were recruited into the study. The mean age and SD were 
54.48 ±12.94 years and age range of 26 to 86 years old. Fifty seven (54.3%) of the 
infected patients were males while forty eight (45.7%) were females.  Based on the 
endoscopic findings, 78 patients had gastritis, nine gastric ulcer, five duodenal ulcer 
and 13 normal. The prevalence of H. pylori cagA, babA2, sabA and dupA genes in H. 
pylori  dyspeptic patients were 69.5%, 41.0%, 43.8% and 22.9% respectively. cagA 
is more common in Indians (39.7%), babA2 is common in Malays (39.5%) and dupA 
detection is more in Indian and Malay at the same rate (37.5%). The Chinese have 
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the lowest prevalence of the four genes. Majority of Chinese patients were 
predominantly infected with cagA type A-B-D East Asian strain (88.9%) while cagA 
type A-B-C Western strain (82.8%) was predominantly detected in the Indians while 
the Malays have mixed strain. There were statistically significant difference 
(P<0.001) between ethnicity and cagA EPIYA motifs, although we could not find 
significant difference between H. pylori virulence genes and EPIYA types and 
clinical outcomes. In phase II, a total of 80 (42 H. pylori positive and 38 H. pylori 
negative) third generation patients with a mean age of 49.87 ± 12.335 years (age 
range 20-75 years) were recruited. The present study identified SNPs rs3770521 
(P=1.33 x 10
-5
) of XRCC5 gene, rs7042986 of SMARCA2 (P=0.0001) and 
rs10860808 (P=0.0002) of DRAM1 gene as the susceptible SNPs to H. pylori 
infection among the Indian, Malay and Chinese gastritis patients respectively. This 
study also identified two protective SNPs rs1809578 (P=9.85x 10
-6
) of gene BANK1 
and rs3776349 (P=0.0001) of gene ARHGAP26 among H. pylori the Indian and 
Malay gastritis patients respectively. In conclusion, the lower prevalence of virulence 
genes and variations among the different ethnic groups suggest that the bacterial 
strains are geographically and ethnically dependent.  No significant difference was 
observed between virulence genes and clinical outcome. This study also shows that 
EPIYA A-B-D and A-B-C are predominant in the Chinese and Indians respectively, 
while the Malays have mixed strain. Finally, the current GWAS study revealed five 
novel SNPs that may be associated with susceptibility and protection of H. pylori 
gastritis in the three ethnic groups. 
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Chapter 1: Introduction  
1.1 H. pylori 
Marshall and Warren, in 1982 were the first to isolate and culture the spiral 
bacterium, now known as H. pylori, from the gastric mucosa of humans (Marshall 
and Warren, 1984). In their first study of more than 100 antral biopsy samples, they 
observed this bacterium to be present by histology in 58 subjects undergoing 
endoscopic examination and were able to isolate and culture it from 11 biopsy 
specimens. Based on these results, Marshall and Warren suggested that there was an 
etiological relationship between H. pylori and these gastric diseases (Marshall and 
Warren, 1984). Therefore in 2005 as recognition of the value of their discovery to the 
medical world, Barry Marshall and Robin Warren were awarded the Nobel Prize in 
Medicine. 
1.2 Historical aspects 
Prior to the discovery by Marshall and Warren, other scientists had also 
observed this bacteria to be present in the gastric mucosa of both humans and 
animals. The first of such report came from Bottcher in 1874 in which he described 
the bacteria to be present on the ulcer floor and in the mucosal margins of ulcers. In 
1938, Doenges found spiral organisms in 103 (43%) of 242 stomachs examined at 
autopsy. In 1954, however, Palmer reported no evidence of spiral organisms in 1180 
gastric mucosal biopsies from 1000 patients; he suggested that the organism noted 
previously in normal stomachs represented postmortem processes and that the 
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bacterial source was the oral cavity. In 1975, Steer and Colin-Jones reported the 
presence of Gram-negative bacteria in the gastric mucosa of approximately 80% of 
patients with gastric ulcers (Ha, 2007). 
Due to the low pH of gastric acid, the human stomach was long believed to 
be a sterile environment. Although some isolated reports had been made regarding 
the existence of bacteria in the stomach, since the 1800‟s, it was not until 1982 that 
the major breakthrough in the understanding of gastric and duodenal pathology such 
as gastritis, peptic ulcer and gastric cancer occurred when Robin Warren and Barry 
Marshall  described “unidentified curved bacilli on gastric epithelium in active 
chronic gastritis (Robin Warren and Marshall, 1983). 
1.3 Taxonomy 
H. pylori was originally considered as a Campylobacter-like organism (CLO) 
and was named Campylobacter pyloridis (Marshall and Warren, 1984),  based on 
bacterial similarity with other Campylobacter species. In 1987 this name was 
corrected for grammatical reasons to Campylobacter  pylori (Marshall and Goodwin, 
1987). However, based on differences in the 16S rRNA gene sequences, fatty acid 
profiles and flagella morphology, this bacterium was placed in new genus called 
Helicobacter with the new name for this bacterium being H. pylori. The name 
“Helicobacter” was based on the helical shape of the bacterium and the word 
“pylori” was used because the bacterium was commonly isolated from the pylorus of 
the stomach ( Goodwin et al., 1989). 
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1.4 Microbiological features and growth requirements 
Helicobacter belongs to the family Helicobacteraceae, order 
Campylobacterales and the Epsilonproteobacteria class (Owen, 1998). H. pylori is a 
Gram negative spiral rod with 2 – 4 µm in length and 0.5 – 1µm wide. The bacterium 
can appear as rod, while coccodi shapes appear after prolonged in vitro culture or 
antibiotic treatment (Kusters et al., 1997). It has 2 to 6 unipolar, sheathed flagella of 
nearly 3 μm in lengths, which frequently carry a unique bulb at the end. The main 
function of flagella is to allow quick movement in viscous solutions such as the 
mucus layer overlying the gastric epithelial cells (O'Toole et al., 2000). 
H. pylori is a slow-growing microaerophiles, fastidious microorganism and 
require complex growth media. It grows optimally at 37°C on a rich medium 
containing blood or serum.  These supplements may act as additional sources of 
nutrients and possibly also protect against the toxic effects. Media mostly used for 
routine isolation and culture of H. pylori consist of Columbia or Brucella agar 
supplemented with either (lysed) horse or sheep blood or, alternatively, new-born or 
fetal calf serum. For isolation, selective antibiotic mixtures are available (Owen, 
1998; Ndip et al., 2003). Dent supplement consists of vancomycin, trimethoprim, 
cefsoludin, and amphotericin B, whereas Skirrow supplement consists of 
vancomycin, trimethoprim, polymyxin B, and amphotericin B. Liquid media usually 
consist of Brucella, Mueller-Hinton, or brain heart infusion broth supplemented with 
2 to 10% calf serum or 0.2 to 1.0% -cyclodextrins, often together with either Dent or 
Skirrow‟s supplement (Ndip et al., 2003). H. pylori can be identified by Gram 
staining, oxidase, catalase, and urease test (Maaroos et al., 2004). 
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Currently, at least 32 Helicobacter species have been identified in humans and 
animals (http://www.bacterio.cict.fr/h/helicobacter.html). These are generally 
divided into two groups based on the niche they colonise: „gastric‟ Helicobacters 
primarily colonise the stomach whilst „enterohepatic‟ Helicobacters colonise the 
intestine and hepatobiliary system. 
1.5 Epidemiology 
1.5.1 Prevalence 
H. pylori infects more than half of the world‟s population (Ryan et al., 2001; 
Amjad et al., 2010). The prevalence was around 25% in developed countries to more 
than 90% in developing areas, but not all infected individuals eventually developed 
the disease (Figure 1.1)  (van Doorn et al., 2000; Ribeiro et al., 2003). The 
prevalence of H. pylori infection varies widely by geographic area, age, race, and 
socioeconomic status (Brown, 2000). The prevalence varies from one country to 
another for example in Australia, it is as low as 15.5% (Pandeya and Whiteman, 
2011), while in India,  as high as 87% (Miwa et al., 2002). Among East Asian 
countries, the overall seroprevalence rate was 59.6% in South Korea (Yim et al., 
2007), 58.07% in China (Wang and Wang, 2003), 54.5% in Taiwan and 39.3% in 
Japan (Fock, 2014).  Among Southeast Asian countries, the reported sero prevalence 
rate was 35.9% in Malaysia (Goh and Parasakthi, 2001), 31% in Singapore (Fock, 
2014) and 57% in Thailand (Deankanob et al., 2006). 
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 H. pylori prevalence varies considerably between the three primary ethnic 
groups resident in Malaysia, Malays, Chinese and Indians with prevalence rates of   
8-43.3%, 45-60.6% and 68.9-75% respectively (Ramelah et al., 2005; Tan et al., 
2005). H. pylori acquisition is declining in developed countries at a faster rate as 
compared to developing countries, because of the improvement in hygiene practices 
in the developed world (Brown, 2000). In 1994, on the basis of various 
epidemiological studies, H. pylori was classified as a class I carcinogen in humans by 
a working group of the World Health Organization International Agency for 
Research on Cancer (Yamazaki et al., 2005b). 
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Figure ‎1.1 World-wide distribution of H. pylori infection adapted from (Bauer and 
Meyer, 2011) 
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1.5.2 Transmission and source of infection 
The exact mechanisms whereby H. pylori is acquired are largely unknown. H. 
pylori is almost always acquired in childhood. The only known reservoir for H. 
pylori is the human stomach.  Person to person spread appears to be the most likely 
mode of transmission (Quinn et al., 2003)  Transmission has been documented by 
vomitus, saliva, or faeces and possibly also through water source in the developing 
world (Brown et al., 2002). 
Convincing evidence of intrafamilial transmission, particularly parent to 
child, has been provided by various studies showing an intrafamilial clustering of 
infection (Kivi et al., 2003; Perez-Perez et al., 2004; Schwarz et al., 2008; Nahar et 
al., 2009). Studies have found that iatrogenic transmission occurs through use of a 
variety of inadequately disinfected gastric devices, endoscopes, and endoscopic 
accessories. Adequate sterilization and disinfection of endoscopes has been found to 
reduce the incidence of transmission  (Muhammad et al., 2012). 
Faeco-oral transmission and oral-oral transmission of bacteria have been 
reported. Contaminated water supplies in developing countries may serve as an 
environmental source of bacteria. Children who regularly swim in rivers, streams, 
pools, drink stream water, or eat uncooked vegetables have greater chance of 
infection (Muhammad et al., 2012).  In the absence of treatment, infection is usually 
lifelong.  The major risk factor for infection is poor socio-economic conditions in 
childhood (Malaty and Graham, 1994), overcrowding and ethnic and genetic 
predisposition (Das and Paul, 2007).  
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1.5.3 H. pylori as a tool for tracking human migration 
H. pylori strains from different geographic areas demonstrate 
phylogeographical differentiation; therefore, the genotypes of H. pylori strains can 
serve as markers of the migration of human populations. Thus, the genotypes of H. 
pylori virulence factors, cagA and vacA, as well as multilocus sequence typing 
(MLST), are widely used markers of genomic diversity in H. pylori populations. The 
cagA virulence factor has two types: the East Asian and the Western types (Yamaoka 
et al., 2000b; Yamaoka, 2009). H. pylori infection has rapidly declined because 
personal hygiene and quality of life have improved. The molecular epidemiology of 
H. pylori infection is highly informative and should be investigated before this 
characteristic is completely lost. 
The MLST of seven housekeeping genes has been obtained from several H. 
pylori strains isolated from different geographical and ethnic origins; MLST results 
have shown that H. pylori has followed human migration from Africa (Falush et al., 
2003). For instance, six H. pylori populations, including hpAfrica1, hpAfrica2, 
hpNEAfrica, hpEurope, hpEastAsia, and hpAsia2, have been identified, indicating H. 
pylori has migrated with its host from Africa (Falush et al., 2003). hpEastAsia 
comprises hspAmerInd, hspMaori, and hspAsia; hpEurope includes strains from 
Europe, Turkey, Bangladesh, Ladakha (India), Sudan, and Israel. Interestingly, 
isolates from Europe form a heterogeneous population, in which the modern 
hpEurope population is a combination of two ancestral European populations that 
likely settled in Europe in different waves (Falush et al., 2003). A recent study done 
in Malaysian Malay, Chinese and Indian showed variations in population. 
hpEastAsia has been isolated from Chinese patients; furthermore, hpAsia2 isolates 
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have been obtained from Indians. Isolates from Malay patients comprise a mixed 
group; these isolates are similar to hspIndia subpopulation (Falush et al., 2003; Tay 
et al., 2009). The low prevalence of infection and the variation of Malay isolates 
imply that Malays were originally free of H. pylori but recently acquired the 
pathogen from other subpopulations, mainly from Indians (Tay et al., 2009). It has 
been established that H. pylori cagA EPIYA patterns have a significant geographic 
variability and closely follow patterns of historical human migrations. EPIYA D is a 
characteristic Asian EPIYA pattern that virtually does not occur in the Western H. 
pylori strains (EPIYA C) (Queiroz et al., 2010).  
1.6 Pathogenicity and virulence factors of H. pylori 
H. pylori is a Gram-negative spiral bacterium that colonizes and persists in 
human gastric mucosa. H. pylori infects more than half of the world‟s population, 
and it is implicated as a causative agent of gastritis, peptic ulcer disease, carcinoma, 
and mucosa-associated lymphoid tissue lymphoma (Ryan et al., 2001; Bindayna et 
al., 2006).  It is one of the most common bacterial infections in humans (Blaser, 
1997). H. pylori strains have been divided into two broad families, type I and type II, 
which are based on whether or not they possess the vacA and cagA genes. Type I 
strains have the ability to produce VacA and CagA, while type II strains lack that 
ability. Type I strains are regarded as having greater pathogenicity and potential to 
cause development of disease (Yamazaki et al., 2005b). H. pylori possesses a number 
of virulence factors that allow it to colonize the harsh environment of the stomach, 
with many of these factors also implicated in its pathogenesis. Among these are 
urease, flagella, cagA, cagA EPIYA motifs, vacA,dupA, babA and sabA. 
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Figure ‎1.2 Schematic diagram of colonization as the first step in H. pylori infection 
adapted from  (Sheu et al., 2010). 
Figure 1.2 shows the urease activity and flagella of H. pylori facilitate its orientation 
to the lower one-fourth of the mucus gel above the epithelium. Several putative 
adhesion molecules, including babA, SabA, Lewis antigen, and other outer 
membrane proteins (OMPs) are ready to adhere to known or unknown counterpart 
receptors on the host the epithelium. (Sheu et al., 2010). 
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1.6.1 Urease  
One of the prominent features of H. pylori its ability to colonize the acidic 
gastric environment, although the bacterium is not an acidophile it overcomes the 
acidic conditions by production of urease enzyme (Kusters et al., 2006). H. pylori 
survives at a pH range between 4.0 and 8.0 in the absence of urea. However, in the 
presence of urea the organism can survive at a pH as low as 2.5 (Dunne et al., 2014).  
In the stomach the H. pylori urease enzyme converts urea into ammonia and 
carbon dioxide. The ammonia helps to neutralize the acidic environment around the 
bacterium and enable H. pylori to survive and multiply in the stomach (Andersen, 
2007). 
1.6.2 Flagella  
Motility is essential for H. pylori colonization.  Flagellar motility is thought 
to be required for the initial stages of infection allowing the bacterium to move from 
acidic environment of the gastric lumen into less acidic mucus layer (Thompson et 
al., 2003). H. pylori carries 5-7 sheathed flagella that perform the motility required 
for colonization and infection. The flagella filament consists of two subunits. Both 
genes coding for these flagellins are necessary for full motility of H. pylori. The 
sheathing of the flagella is believed to protect them from the acidic environment in 
the stomach.(Andersen, 2007). 
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1.6.3 Cytotoxin-associated gene A (cagA) 
CagA is the most widely studied H. pylori virulence factor and is present in 
many but not all H. pylori strain (Covacci et al., 1993). The cagA gene is located at 
one end of the cag pathogenicity island (PAI) that codes a type IV secretion system 
(T4SS) linked with increased secretion of IL-8, a very strong pro-inflammatory 
chemokine that participates in the gastritis induced by H. pylori infection. The T4SS 
is also liable for the entrance of cagA protein into the gastric epithelial cells. After 
the delivery, cagA protein is quickly tyrosine phosphorylated on specific tyrosine 
residues within repeating Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs and interacts with 
various target molecules (Naito et al., 2006). Studies have shown that knockout 
mutants of  TFSS genes could not undertake cagA transfer and as a result cagA 
tyrosine phosphorylation did not occur. This means that for a functional cagA 
translocation, the TFSS genes must be intact (Stein et al., 2000). 
The phosphorylated EPIYA motifs of cagA interact and activate the Src 
homology 2 (SH2) domain-containing tyrosine phosphatase (SHP-2) of the host 
cells. The cagA-SHP-2 complex leads to change in proliferation, morphogenesis and 
motility of gastric epithelial cells and hence inducing the “hummingbird” phenotype 
(cell elongation). As  SHP-2 plays an important role in both cell growth and cell 
motility, deregulation of SHP-2 by cagA may be involved in the induction of 
abnormal proliferation and movement of gastric epithelial cells, a cellular condition 
eventually leading to gastritis and gastric carcinoma (Backert et al., 2001; Higashi et 
al., 2002a; Yamazaki et al., 2003). 
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CagA-positive H. pylori strains are most virulent strains and are associated 
with higher risk for peptic ulcers (Oleastro et al., 2003; Ribeiro et al., 2003; 
Yamazaki et al., 2005b). Several studies based on a few strains demonstrated that 
cagA-positive H. pylori isolates, but not cagA-negative isolates, were able to induce 
interleukin 8 (IL-8) secretion in vitro and in vivo (Huang et al., 1995; Sharma et al., 
1995). Therefore the ability to induce IL-8 secretion is recognized as one of the 
major virulence factors of H. pylori and seems to be important in the establishment 
of PUD (Peek et al., 1995). 
It has been reported that cagA gene is present in approximately 60% of H. 
pylori strains from Western populations, but in contrast, it is present in over 90% of 
the strains from Southeast Asian populations (Chen et al., 2005; Siavoshi et al., 
2005). CagA gene is considered as a marker to predict the severity of peptic ulcer 
disease in European and North American populations (Covacci et al., 1993). The 
presence of cagA has been associated with peptic ulcer disease and gastric cancer 
(Miehlke et al., 2001). 
1.6.3.1 cagA EPIYA motifs 
cagA is a polymorphic gene that presents different numbers of repeated 
sequences located in its 3' region. Each repeated region of cagA protein contains Glu-
Pro-Ile-Tyr-Ala (EPIYA) motifs, including a tyrosine phosphorylation site 
(Hatakeyama, 2004). Four distinct EPIYA sites have been described, EPIYA-A, 
EPIYA-B, EPIYA-C and EPIYA-D each of which is conserved in sequence.  In  
Europe, North America, and Australia, many H. pylori isolates cagA carries EPIYA-
A, EPIYA-B and EPIYA-C segments in tandem and is called Western type and 
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shown in figure 2.3. In  East Asian countries such as Japan, Korea and China cagA 
carries EPIYA-A, EPIYA-B and EPIYA-D segments in tandem and is called East 
Asian type and shown in figure 2.3 (Higashi et al., 2002b). The EPIYA-C segment 
multiplies (mostly one to three times) in tandem among different Western cagA 
species. CagA from East Asian H. pylori isolates also possesses EPIYA-A and 
EPIYA-B segments, but not the repeatable EPIYA-C segment. Instead, it has 
EPIYA-D segment, which is unique to East Asian cagA (Hatakeyama, 2009).  The 
EPIYA-C segment is found in Western cagA and it includes hpAfrica1, hpEurope, 
hpNEAfrica strains and some hpAsia2 strains from Southeast Asia, while the 
EPIYA-D segment is unique for East-Asian cagA in hpEastAsia strains and in some 
hpAsia2 strains from Ladakh in Northern India (Olbermann et al., 2010).  
Majority of H. pylori isolates in East Asian countries possess East Asian 
cagA. In contrast, nearly all H. pylori cagA-positive strains isolated in Western 
countries carry Western cagA (Figure 1.3). Interestingly, in Southeast Asia countries 
like Malaysia, Thailand, Philippines and Vietnam  (Hatakeyama, 2011). East Asian 
(ABD) cagA-carrying H. pylori and Western (ABC) cagA-carrying H. pylori may 
have been introduced into Southeast Asian people through migrations of ethnic 
Chinese and ethnic Indian people, respectively (Graham et al., 2007; Yamaoka, 
2009; Sahara et al., 2012). 
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Figure ‎1.3 Worldwide distribution of H. pylori Western cagA and East Asian cagA 
Western cagA shown in yellow and East Asian cagA in orange colour, 
Adapted from  (Hatakeyama, 2011).  
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More than 60% of Western CagA proteins carry the EPIYA-ABC, followed 
by the EPIYA-ABCC 20.3%, then the EPIYA-ABCCC 4.0% as shown in Figure 2.4 
(Hatakeyama, 2011).  In contrast to the EPIYA-C segment, the EPIYA-D segment 
seldom duplicates and thus majority of the East Asian CagA isolates contain a single 
EPIYA-D segment (98.8%), which, in many cases, is present in EPIYA-ABD 
(Figure 1.4) (Xia et al., 2009). 
EPIYA type D or multiple C repeats is associated with increased SHP-2 
phosphatase activity induced by cagA. Strains possessing cagA with greater numbers 
of type C phosphorylation motifs predispose to precancerous lesions and gastric 
cancer (Azuma et al., 2002; Naito et al., 2006). Thus, determination of the degree of 
cagA phosphorylation or the number of phosphorylation motifs appears to be more 
important than detection of cagA alone (Argent et al., 2005). 
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Figure ‎1.4 Structural polymorphisms in cagA and cagA multimerization (CM) 
sequence adapted from (Hatakeyama, 2011). 
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1.6.4 Vacuolating cytotoxin gene A (vacA) 
The vacA gene is present in all H. pylori strains and encodes a vacuolating 
cytotoxin. There are at least four vacA signal sequence types (s1a, s1b, s1c, and s2) 
and two middle region types (m1, m2) (Ben Mansour et al., 2010).  Type s1/m1 
mosaic combination strains express more cytotoxin activity than s1/m2 strains, and 
s2/m2 strains produce no detectable cytotoxin activity (van Doorn et al., 1998; Ben 
Mansour et al., 2010). Mature VacA s1-type strains has a hydrophobic N terminal 
region which is able to insert into the host cell membrane leading to vacuolation, 
whereas non-toxigenic s2- type strains have an N-terminus preceded by a hydrophilic 
region that blocks vacuolation  (McClain et al., 2001).  H. pylori vacA type s1 strains 
seems to be more virulent than type s2 strains and are associated with higher risks for 
peptic ulcer disease, gastric atrophy, and gastric carcinoma (Figueiredo et al., 2002). 
There is geographical variation in the vacA genotypes. In Western country, 
including Latin America and Africa, studies have reported that individuals infected 
with s1 or m1 H. pylori strains have an increased risk of peptic ulcer or Gastric 
cancer compared with individuals infected with s2 or m2 strains (Sugimoto and 
Yamaoka, 2009).  There is also a variation of m strain within East Asia; for instance, 
where m1 strains are common in parts of Northeast Asia, such as Japan and South 
Korea and m2 strains being predominant in parts of Southeast Asia, such as Taiwan 
and Vietnam (Yamaoka et al., 2002; Uchida et al., 2009). 
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1.6.5 Duodenal ulcer promoting gene (dupA) 
dupA, which is located in the plasticity region of H. pylori genome,  has been 
found to be a risk factor for duodenal ulcer (DU) and a protective factor against 
gastric cancer (GC) in Japan and Korea (Lu et al., 2005). The dupA gene contains 
two continuous sequences, jhp0917 and jhp0918 which was initially reported to be a 
marker for DU development, but some studies showed that this gene can also be 
associated with GC (Argent et al., 2007; Schmidt et al., 2009a). Studies in patients 
from Brazil, India, China, USA, South Africa, Belgium, Iraq and Iran have 
confirmed that jhp0917 and jhp0198 are both present and form a continuous ORF, 
they have been unable to consistently replicate an association with gastroduodenal 
disease (Arachchi et al., 2007; Douraghi et al., 2008; Hussein et al., 2008; Zhang et 
al., 2008). A recent meta-analysis by Hussein et al. has concluded that the effects of 
dupA may be population specific, predisposing to DU in some populations and GC 
and GU in others (Hussein, 2010).  Recently, dupA has been shown to play an 
important role in provoking IL-8 secretion (Queiroz et al., 2011). In East Asian 
region this gene has been linked with the high risk of GC development. In the study 
that identified cagA gene in all samples as well suggesting that combination of these 
genes, may underline the high risk of GC in this area (Wang et al., 2013). 
1.6.6  Blood-group antigen binding adhesin (babA) 
Attachment of H. pylori to the gastric epithelium is thought to be a major 
contributor to H. pylori persistence by providing access to nutrients and protection 
from gastric acid and mucus turnover. H. pylori outer membrane proteins (OMPs) 
have been proposed to be critical for adaptation to the host and persistent 
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colonisation. Indeed, the attachment is mediated by several OMPs, the best 
characterised of which are the Lewis(Le)b blood-group antigen binding adhesin 
(babA), the outer membrane inflammatory protein (OipA) and the sialic acid binding 
adhesin (SabA) (Ilver et al., 1998). 
BabA is a blood-group antigen-binding adhesin encoded by the babA2 gene, 
which has been shown to mediate adherence of H. pylori to human Lewis b blood-
group (Leb) antigens  (Gerhard et al., 1999). Although three bab alleles have been 
identified (babA1, babA2 and babB), only the babA2 gene product is functional for 
Leb binding activity (Pride et al., 2001). Studies in Western countries have disclosed 
associations between the presence of babA2 gene and digestive diseases such as 
duodenal ulcer and gastric cancer (Gerhard et al., 1999). However, in Asia, most of 
the H. pylori strains are babA2-positive, irrespective of clinical outcome (Mizushima 
et al., 2001; Sheu et al., 2003). A study done in Iranian patients recently reported that 
babA2 distribution was significantly higher in GC subjects (95%) when compared 
with non-ulcer dyspepsia patients (26.1%) and DU patients (Talebi Bezmin Abadi et 
al., 2013)  Thus, conclusions about the relationship between H. pylori genotypes and 
clinical outcome derived from one geographic region may not be true for other 
geographic regions. 
1.6.7 Sialic acid-binding adhesin (sabA) 
H. pylori OMP, the sialic acid-binding adhesin (SabA), binds to sialylated 
carbohydrate structures, which are upregulated as part of complex gangliosides in 
inflamed gastric tissue. The capacity to bind to the glycosylated epithelial cells is 
considered to be important for H. pylori to cause constant infection and disease 
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(Aspholm et al., 2006; Odenbreit et al., 2009). SabA was postulated to contribute to 
the chronic persistence of the infection (Mahdavi et al., 2002; Aspholm et al., 2006). 
Investigation of the role of SabA in disease development has gained momentum over 
the last few years, with evidence suggesting that sabA not only plays a role in disease 
development but that this role may be consistent across populations. For example, a 
study of a developing Hispanic country (Columbia) and a developed Caucasian 
country (USA) found a similarly increased prevalence of sabA in DU and GC in both 
populations (Yamaoka et al., 2006). It has also been reported that the off status of 
sabA is associated with DU, but not GU, suggesting that sabA may be a reliable 
marker for specific disease outcome (de Jonge et al., 2004). However, a more recent 
study in Taiwan found no association with disease (Sheu et al., 2006). 
1.7 H. pylori  and clinical outcome 
H. pylori infection is found to be associated with gastritis, DU, GU, non-ulcer 
dyspepsia, GC and gastric lymphoma of mucosa associated lymphoid tissue (MALT) 
(Figure 2.5). Infection usually occurs during childhood and causes symptomatic 
acute gastritis in most patients and persists for decades or life-long, the infection can 
take multiple courses.  Most people infected with H. pylori usually show no 
developing symptomatic disease; however, 10-15 % will develop peptic ulcer 
disease, approximately 1% will develop gastric adenocarcinoma, while a small group 
of patients will develop gastric mucosa associated lymphoid tissue lymphoma 
(MALToma) (Wu et al., 2008; Varbanova and Malfertheiner, 2011). A normal or 
high acid secretion predisposes to duodenal ulcers (DU), whereas a low acid 
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secretion predisposes to gastric ulcers (GU) and gastric cancer (GC) (Gerrits et al., 
2006) as indicated in Figure 1.5. 
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Figure ‎1.5 Modified natural history of H. pylori  infection adapted from (Conteduca 
et al., 2013). 
 
 
 
 
 
 
 
High acid secretion 
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Patients with increased acid secretion are likely to have antral-predominant 
gastritis, which predisposes to duodenal ulcers. Patients with low acid secretion will 
more likely develop gastritis in the body of the stomach and are thus more likely to 
develop gastric ulcer, leading to gastric atrophy, intestinal metaplasia, dysplasia and 
in rare cases, gastric carcinoma. This sequence of events is more frequent in people 
of advanced age. H. pylori infection induces the formation of mucosa-associated 
lymphoid tissue (MALT) in the gastric mucosa and MALT lymphoma is another rare 
complication of H. pylori infection (Figure 1.5). 
The gastric mucosa is well protected against bacterial infections.  H. pylori is 
adapted to this ecologic niche, with a array of features that permit entry into the 
mucus, swimming spatial orientation in the mucus, attachment to epithelial cells, 
evasion of the immune response and as a result persistent colonization and 
transmission (Suerbaum and Michetti, 2002). After being ingested, the bacteria have 
to evade the bactericidal activity of the gastric luminal contents and enter the mucous 
layer.  Urease production and motility are essential for this first step of infection. 
Urease hydrolyzes urea into carbon dioxide and ammonia, thereby permitting H. 
pylori to survive in an acid milieu (Weeks et al., 2000; Dhar et al., 2003). 
1.7.1 Gastritis 
Gastritis refers to inflammation of the gastric mucosa. When a person is 
infected with H. pylori the initial response to infection is the development of an acute 
gastritis. This acute phase is characterized by the presence of fever, vomiting, nausea 
